Literature DB >> 26303825

Lymph node evaluation for treatment of adenocarcinoma of the pancreas.

Schelomo Marmor1, Erin E Burke1, Pamela R Portschy1, Beth A Virnig2, Eric H Jensen1, Todd M Tuttle3.   

Abstract

BACKGROUND: Increased lymph node evaluation has been associated with improved survival rates in patients with pancreatic cancer. We sought to evaluate the trends and factors associated with lymph node examination over time and the effects on survival.
METHODS: Using the Surveillance, Epidemiology and End Results database, we conducted an analysis of adults with adenocarcinoma of the pancreas who underwent surgical resection. Using the Cochrane Armitage test for trend and logistic regression we identified factors associated with lymph node evaluation. Kaplan-Meier and Cox proportional hazards modeling were used to examine survival.
RESULTS: We identified 4831 patients who underwent surgical resection from 1990 to 2010. The proportion of patients with 15 or more lymph nodes evaluated increased from 16% to 42% (p < 0.05) and the median number of lymph nodes examined increased from 7 to 15 nodes (p < 0.05) during the study period. Overall, 56% of patients had lymph node metastases; this proportion significantly increased during the study period. Factors that were independently associated with less than 15 lymph nodes evaluated included male gender, receipt of pre-operative radiation therapy, early year of diagnosis, older age, and missing information on tumor grade and size (p < 0.05). Survival rates significantly improved when 15 or more lymph nodes were examined.
CONCLUSION: We observed a significant increase in the number of lymph nodes evaluated with pancreas cancer resection over time. Lymph node evaluation was significantly associated with patient, tumor, and treatment characteristics. Our results suggest that adequate lymph node evaluation is associated with improved survival.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Lymph node evaluation; Pancreatic adenocarcinoma

Mesh:

Year:  2015        PMID: 26303825     DOI: 10.1016/j.suronc.2015.06.006

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  6 in total

1.  Analysis on survival and prognostic factors in patients with resectable pancreatic adenocarcinoma.

Authors:  Rong Lin; Chao-Qun Han; Wei-Jun Wang; Jun Liu; Wei Qian; Zhen Ding; Xiao-Hua Hou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-08-08

2.  Increased pancreatic cancer survival with greater lymph node retrieval in the National Cancer Data Base.

Authors:  Carlo M Contreras; Chee Paul Lin; Robert A Oster; Sushanth Reddy; Thomas Wang; Selwyn Vickers; Martin Heslin
Journal:  Am J Surg       Date:  2017-07-01       Impact factor: 2.565

3.  Dynamic enhanced CT: is there a difference between liver metastases of gastroenteropancreatic neuroendocrine tumor and adenocarcinoma.

Authors:  Yong Cui; Zhong-Wu Li; Xiao-Ting Li; Shun-Yu Gao; Ying Li; Jie Li; Hui-Ci Zhu; Lei Tang; Kun Cao; Ying-Shi Sun
Journal:  Oncotarget       Date:  2017-11-20

4.  Predictive Model of Early Death of Resectable Pancreatic Ductal Adenocarcinoma After Curative Resection: A SEER-Based Study.

Authors:  Weikang Liu; Yongsu Ma; Bingjun Tang; Chang Qu; Yiran Chen; Yinmo Yang; Xiaodong Tian
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

5.  Adjusting CA19-9 values with clinical stage and bilirubin to better predict survival of resectable pancreatic cancer patients: 5-year-follow-up of a single center.

Authors:  Zuowei Wu; Pengcheng Zhao; Zihe Wang; Xing Huang; Chao Wu; Mao Li; Li Wang; Bole Tian
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

6.  Prognostic impact of lymph node status in patients after total pancreatectomy for pancreatic ductal adenocarcinoma: A strobe-compliant study.

Authors:  Zhen-Jiang Zheng; Mo-Jin Wang; Chun-Lu Tan; Yong-Hua Chen; Jie Ping; Xu-Bao Liu
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.